Biomarkers of primary and acquired resistance are essential to identify patients in which the solely VEGF blockade allows tumor to carry on angiogenesis through different pathways (i.e., PDGFR, fibroblast growth factor receptor (FGFR), MET, etc.). The gene discussed is VEGFA; the disease is neoplasm.